fluconazole has been researched along with 2019 Novel Coronavirus Disease in 18 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Several institutions reported a rise not only in fungemia incidence but also in the number of cases caused by Candida auris or fluconazole-resistant C." | 4.31 | Yeasts from blood cultures in the wake of the COVID-19 pandemic in a tertiary care hospital: Shift in species epidemiology, steady low antifungal resistance and full in vitro ibrexafungerp activity. ( Díaz-García, J; Escribano, P; Guinea, J; Machado, M; Mesquida, A; Muñoz, P; Sánchez-Carrillo, C, 2023) |
| "Pyelonephritis was associated with caliectasis and obstruction due to possible fungus ball formation." | 2.82 | Invasive Candida kefyr infection presenting as pyelonephritis in an ICU hospitalized COVID-19 patient: Case report and review of the literature. ( Kolonitsiou, F; Lekkou, A; Paliogianni, F; Spiliopoulou, A; Tsoupra, S; Vrioni, G, 2022) |
| "The prevalence of fungal secondary infections among COVID-19 patients and efficacy of antifungal therapy used in such patients is still unknown." | 2.82 | Antifungal therapy in the management of fungal secondary infections in COVID-19 patients: A systematic review and meta-analysis. ( Kumar, TMP; Pathakamuri, N; Ramaswamy, S; Ramesh, M; Sah, SK; Shariff, A; Srikanth, MS; Undela, K, 2022) |
| "Although "Candida pneumonia" is rarely being reported in critically ill patients, Candida airway colonization mainly by Candida albicans is common especially among patients with diabetes, malignancies, and kidney disorders." | 1.72 | Clinical impact of Candida respiratory tract colonization and acute lung infections in critically ill patients with COVID-19 pneumonia. ( Amiri, S; Erami, M; Fakhrehi, M; Getso, MI; Hashemi, SJ; Mehri, N; Momen-Heravi, M; Raiesi, O; Raissi, V; Yarahmadi, M, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 18 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Escandón, P | 1 |
| Cáceres, DH | 1 |
| Lizarazo, D | 1 |
| Lockhart, SR | 1 |
| Lyman, M | 1 |
| Duarte, C | 1 |
| Spiliopoulou, A | 1 |
| Kolonitsiou, F | 1 |
| Vrioni, G | 1 |
| Tsoupra, S | 1 |
| Lekkou, A | 1 |
| Paliogianni, F | 1 |
| Madrigal-Aguilar, DA | 1 |
| Gonzalez-Silva, A | 1 |
| Rosales-Acosta, B | 1 |
| Bautista-Crescencio, C | 1 |
| Ortiz-Álvarez, J | 1 |
| Escalante, CH | 1 |
| Sánchez-Navarrete, J | 1 |
| Hernández-Rodríguez, C | 1 |
| Chamorro-Cevallos, G | 1 |
| Tamariz, J | 1 |
| Villa-Tanaca, L | 1 |
| Erami, M | 2 |
| Raiesi, O | 2 |
| Momen-Heravi, M | 2 |
| Getso, MI | 2 |
| Fakhrehi, M | 1 |
| Mehri, N | 2 |
| Yarahmadi, M | 1 |
| Amiri, S | 1 |
| Raissi, V | 1 |
| Hashemi, SJ | 2 |
| Pfaller, MA | 1 |
| Carvalhaes, CG | 1 |
| DeVries, S | 1 |
| Rhomberg, PR | 1 |
| Castanheira, M | 1 |
| Matin, P | 1 |
| Hanee, U | 1 |
| Alam, MS | 1 |
| Jeong, JE | 1 |
| Matin, MM | 1 |
| Rahman, MR | 1 |
| Mahmud, S | 1 |
| Alshahrani, MM | 1 |
| Kim, B | 1 |
| Sah, SK | 1 |
| Shariff, A | 1 |
| Pathakamuri, N | 1 |
| Ramaswamy, S | 1 |
| Ramesh, M | 1 |
| Undela, K | 1 |
| Srikanth, MS | 1 |
| Kumar, TMP | 1 |
| Fattahi, M | 1 |
| Daie Ghazvini, R | 1 |
| Khodavaisy, S | 1 |
| Parviz, S | 1 |
| Babaei, M | 1 |
| McClatchy, J | 1 |
| Yap, T | 1 |
| Nirenberg, A | 1 |
| Scardamaglia, L | 1 |
| Yazdanpanah, S | 2 |
| Ahmadi, M | 2 |
| Zare, Z | 2 |
| Nikoupour, H | 2 |
| Arabsheybani, S | 2 |
| Jabrodini, A | 2 |
| Eghtedarnejad, E | 2 |
| Chamanpara, P | 2 |
| Geramizadeh, B | 2 |
| Anbardar, MH | 2 |
| Malekizadeh, Z | 2 |
| Gashtasebi, M | 2 |
| Mohsenzadeh, M | 2 |
| Shafiekhani, M | 2 |
| Zomorodian, K | 2 |
| Tsai, CS | 1 |
| Lee, SS | 1 |
| Chen, WC | 1 |
| Tseng, CH | 1 |
| Lee, NY | 1 |
| Chen, PL | 1 |
| Li, MC | 1 |
| Syue, LS | 1 |
| Lo, CL | 1 |
| Ko, WC | 1 |
| Hung, YP | 1 |
| Rawas-Qalaji, M | 1 |
| Jagal, J | 1 |
| Fayed, B | 1 |
| Hamdy, R | 1 |
| Soliman, SSM | 1 |
| Díaz-García, J | 1 |
| Mesquida, A | 1 |
| Machado, M | 1 |
| Sánchez-Carrillo, C | 1 |
| Muñoz, P | 1 |
| Escribano, P | 1 |
| Guinea, J | 1 |
| Rząd, K | 1 |
| Ioannidi, R | 1 |
| Marakos, P | 1 |
| Pouli, N | 1 |
| Olszewski, M | 1 |
| Kostakis, IK | 1 |
| Gabriel, I | 1 |
| Szekely, J | 1 |
| Rakchang, W | 1 |
| Rattanaphan, P | 1 |
| Kositpantawong, N | 1 |
| Bruni, F | 1 |
| Di Altobrando, A | 1 |
| Alessandrini, A | 1 |
| Starace, M | 1 |
| Piraccini, BM | 1 |
| Vincenzi, C | 1 |
| Bhagali, R | 1 |
| Prabhudesai, NP | 1 |
| Prabhudesai, MN | 1 |
| Nobrega de Almeida, J | 1 |
| Brandão, IB | 1 |
| Francisco, EC | 1 |
| de Almeida, SLR | 1 |
| de Oliveira Dias, P | 1 |
| Pereira, FM | 1 |
| Santos Ferreira, F | 1 |
| de Andrade, TS | 1 |
| de Miranda Costa, MM | 1 |
| de Souza Jordão, RT | 1 |
| Meis, JF | 1 |
| Colombo, AL | 1 |
4 reviews available for fluconazole and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Invasive Candida kefyr infection presenting as pyelonephritis in an ICU hospitalized COVID-19 patient: Case report and review of the literature.
Topics: Adult; Antifungal Agents; Candida; Candidiasis; Candidiasis, Invasive; COVID-19; Fluconazole; Humans | 2022 |
Antifungal therapy in the management of fungal secondary infections in COVID-19 patients: A systematic review and meta-analysis.
Topics: Antifungal Agents; Coinfection; COVID-19; Fluconazole; Humans; Mycoses; Prospective Studies; Retrosp | 2022 |
Fixed drug eruptions - the common and novel culprits since 2000.
Topics: Acetaminophen; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; COVID-19; COVID-19 Va | 2022 |
COVID-19-associated candidiasis and the emerging concern of Candida auris infections.
Topics: Antifungal Agents; Azoles; Candida auris; Candidiasis, Invasive; COVID-19; Echinocandins; Fluconazol | 2023 |
14 other studies available for fluconazole and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Laboratory-based surveillance of Candida auris in Colombia, 2016-2020.
Topics: Adult; Antifungal Agents; Candida auris; Candidiasis; Child; Colombia; COVID-19; Drug Resistance, Fu | 2022 |
Antifungal Activity of Fibrate-Based Compounds and Substituted Pyrroles That Inhibit the Enzyme 3-Hydroxy-methyl-glutaryl-CoA Reductase of
Topics: Acyl Coenzyme A; Animals; Antifungal Agents; Candida glabrata; COVID-19; Drug Resistance, Fungal; Er | 2022 |
Clinical impact of Candida respiratory tract colonization and acute lung infections in critically ill patients with COVID-19 pneumonia.
Topics: Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candidiasis; Caspofu | 2022 |
Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections.
Topics: Animals; Antifungal Agents; Candida glabrata; Candida parapsilosis; Candida tropicalis; COVID-19; Dr | 2022 |
Novel Galactopyranoside Esters: Synthesis, Mechanism, In Vitro Antimicrobial Evaluation and Molecular Docking Studies.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; COVID-19; Esters; Fluconazole; Gala | 2022 |
COVID-19-associated pulmonary aspergillosis (CAPA) in Iranian patients admitted with severe COVID-19 pneumonia.
Topics: Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus; COVID-19; Fe | 2023 |
Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates.
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis; Coinfection; COVID-19; Drug Resistance, F | 2023 |
Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates.
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis; Coinfection; COVID-19; Drug Resistance, F | 2023 |
Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates.
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis; Coinfection; COVID-19; Drug Resistance, F | 2023 |
Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates.
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis; Coinfection; COVID-19; Drug Resistance, F | 2023 |
Nano-combination for Reviving the Activity of Fluconazole against
Topics: Antifungal Agents; COVID-19; Fluconazole; Humans; Melanins; Microbial Sensitivity Tests; Pandemics; | 2023 |
Yeasts from blood cultures in the wake of the COVID-19 pandemic in a tertiary care hospital: Shift in species epidemiology, steady low antifungal resistance and full in vitro ibrexafungerp activity.
Topics: Animals; Antifungal Agents; Blood Culture; Candida; Candida albicans; Candida glabrata; Candida para | 2023 |
Xanthone synthetic derivatives with high anticandidal activity and positive mycostatic selectivity index values.
Topics: Antifungal Agents; Candida albicans; COVID-19; Drug Resistance, Fungal; Fluconazole; Fungal Proteins | 2023 |
Fluconazole and echinocandin resistance of
Topics: Antifungal Agents; Azoles; Candida; Candidiasis, Invasive; COVID-19; Disease Outbreaks; Echinocandin | 2023 |
Delayed access and provision of dermatological care as a collateral damage of COVID-19-related fear: Allergic contact dermatitis to fluconazole.
Topics: Antifungal Agents; COVID-19; Delayed Diagnosis; Dermatitis, Allergic Contact; Dermatology; Fear; Fem | 2021 |
Post COVID-19 opportunistic candida retinitis: A case report.
Topics: Administration, Oral; Adult; Antifungal Agents; Candidiasis; COVID-19; Eye Infections, Fungal; Fluco | 2021 |
Axillary Digital Thermometers uplifted a multidrug-susceptible Candida auris outbreak among COVID-19 patients in Brazil.
Topics: Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Brazil; Candida; Candidiasis; COVI | 2021 |